T
Tozaro
Innovative reagents simplifying downstream processing for viral vector development in cell and gene therapy
About Tozaro
Tozaro is revolutionizing the bioprocessing landscape by developing a novel suite of reagents designed to simplify and enhance the development and manufacture of viral vectors used in cell and gene therapy. The company operates in the biotechnology sector, specifically targeting the needs of pharmaceutical companies and research institutions involved in advanced therapeutic development. Tozaro's business model focuses on the production and sale of smart polymers and synthetic affinity reagents that streamline downstream processing, making it more intuitive and efficient. Revenue is generated through the sale of these specialized reagents and associated analytical devices, which are crucial for the accurate characterization and quantification of viral particles. The company also engages in technical support and consultancy services to ensure optimal application of their products.
Source: Dealroom company dataAt a glance
- Founded
- 2015
- Headquarters
- Bedford, United Kingdom
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Bill & Melinda Gates Foundation
Series A3 investors entered at this stage
Calculus Capital
Mercia Asset Management
Mercia Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tozaro on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tozaro on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.